These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27271502)

  • 1. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.
    Martin-Mola E; Balsa A; García-Vicuna R; Gómez-Reino J; González-Gay MA; Sanmartí R; Loza E
    Rheumatol Int; 2016 Aug; 36(8):1043-63. PubMed ID: 27271502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
    Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
    Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
    Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
    Aletaha D; Alasti F; Smolen JS
    Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
    Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
    Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
    Kida D; Takahashi N; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Ando M; Kuwatsuka Y; Tanaka E; Yasuoka H; Kaneko Y; Hirata S; Murakami K; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
    Sci Rep; 2020 Nov; 10(1):19717. PubMed ID: 33184461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
    van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
    Alemao E; Postema R; Elbez Y; Mamane C; Finckh A
    Clin Exp Rheumatol; 2020; 38(3):455-466. PubMed ID: 31770089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis.
    Reynisdottir G; Karimi R; Joshua V; Olsen H; Hensvold AH; Harju A; Engström M; Grunewald J; Nyren S; Eklund A; Klareskog L; Sköld CM; Catrina AI
    Arthritis Rheumatol; 2014 Jan; 66(1):31-9. PubMed ID: 24449573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons.
    Alivernini S; Galeazzi M; Peleg H; Tolusso B; Gremese E; Ferraccioli G; Naparstek Y
    Autoimmun Rev; 2017 Nov; 16(11):1096-1102. PubMed ID: 28899798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients.
    Barra L; Scinocca M; Saunders S; Bhayana R; Rohekar S; Racapé M; Coles R; Cairns E; Bell DA
    Arthritis Rheum; 2013 Jun; 65(6):1439-47. PubMed ID: 23450693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis.
    Gonzalez SM; Payne JB; Yu F; Thiele GM; Erickson AR; Johnson PG; Schmid MJ; Cannon GW; Kerr GS; Reimold AM; Sokolove J; Robinson WH; Mikuls TR
    J Periodontol; 2015 Feb; 86(2):222-31. PubMed ID: 25299390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
    Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
    Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.